A multicenter phase II trial of nab-paclitaxel and capecitabine in HER-2 negative and triple- negative advanced breast cancer: Could be an old regimen a valid approach to a changing disease?

GOIM (Gruppo Oncologico dell’Italia Meridionale)

Research output: Contribution to journalComment/debatepeer-review

Original languageEnglish
Pages (from-to)1857-1859
Number of pages3
JournalBreast Journal
Issue number9
Publication statusPublished - Sep 1 2020

ASJC Scopus subject areas

  • Internal Medicine
  • Surgery
  • Oncology

Cite this